Financhill
Sell
36

TECH Quote, Financials, Valuation and Earnings

Last price:
$47.32
Seasonality move :
4.56%
Day range:
$46.27 - $48.87
52-week range:
$46.01 - $83.96
Dividend yield:
0.69%
P/E ratio:
56.90x
P/S ratio:
6.19x
P/B ratio:
3.62x
Volume:
2.3M
Avg. volume:
2.3M
1-year change:
-43.57%
Market cap:
$7.3B
Revenue:
$1.2B
EPS (TTM):
$0.82

Analysts' Opinion

  • Consensus Rating
    Bio-Techne has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $70.11, Bio-Techne has an estimated upside of 50.26% from its current price of $46.66.
  • Price Target Downside
    According to analysts, the lowest downside price target is $51.00 representing 100% downside risk from its current price of $46.66.

Fair Value

  • According to the consensus of 12 analysts, Bio-Techne has 50.26% upside to fair value with a price target of $70.11 per share.

TECH vs. S&P 500

  • Over the past 5 trading days, Bio-Techne has underperformed the S&P 500 by -0.45% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Bio-Techne does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Bio-Techne has grown year-over-year revenues for 19 quarters straight. In the most recent quarter Bio-Techne reported revenues of $316.2M.

Earnings Growth

  • Bio-Techne earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Bio-Techne reported earnings per share of $0.14.
Enterprise value:
7.5B
EV / Invested capital:
3.20x
Price / LTM sales:
6.19x
EV / EBIT:
43.67x
EV / Revenue:
6.21x
PEG ratio (5yr expected):
--
EV / Free cash flow:
33.99x
Price / Operating cash flow:
33.89x
Enterprise value / EBITDA:
26.55x
Gross Profit (TTM):
$794.8M
Return On Assets:
4.89%
Net Income Margin (TTM):
10.89%
Return On Equity:
6.38%
Return On Invested Capital:
5.51%
Operating Margin:
12.24%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Income Statement
Revenue $1.1B $1.2B $1.2B $303.4M $316.2M
Gross Profit $765.5M $771.1M $794.8M $204.6M $214.6M
Operating Income $284.2M $247.4M $208.1M $67M $38.7M
EBITDA $445.6M $359.9M $282.7M $92.4M $67.9M
Diluted EPS $1.67 $1.26 $0.82 $0.31 $0.14
Period Ending 2021-03-31 2022-03-31 2023-03-31 2024-03-31 2025-03-31
Balance Sheet
Current Assets $566.6M $593.1M $571M $610.7M $627.2M
Total Assets $2.1B $2.3B $2.6B $2.7B $2.6B
Current Liabilities $137.6M $166.8M $141.2M $149.8M $169.2M
Total Liabilities $536.7M $586.6M $710M $706.8M $626.2M
Total Equity $1.5B $1.7B $1.9B $2B $2B
Total Debt $215.4M $259M $370M $389M $330M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Cash Flow Statement
Cash Flow Operations $273.7M $306.9M $264.9M $81M $41.1M
Cash From Investing -$279.5M -$199M -$44.4M -$16.4M -$8.9M
Cash From Financing -$18.9M -$86.5M -$223.5M -$52.4M -$68M
Free Cash Flow $232.7M $251.2M $220.8M $64.5M $31M
TECH
Sector
Market Cap
$7.3B
$35M
Price % of 52-Week High
55.57%
43.76%
Dividend Yield
0.69%
0%
Shareholder Yield
--
-0.59%
1-Year Price Total Return
-43.57%
-41.98%
Beta (5-Year)
1.459
0.659
Dividend yield:
0.69%
Annualized payout:
$0.32
Payout ratio:
38.45%
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $49.53
200-day SMA
Sell
Level $67.79
Bollinger Bands (100)
Sell
Level 51.83 - 71.71
Chaikin Money Flow
Buy
Level 60.4M
20-day SMA
Sell
Level $49.72
Relative Strength Index (RSI14)
Sell
Level 39.06
ADX Line
Sell
Level 21.04
Williams %R
Buy
Level -95.203
50-day SMA
Sell
Level $53.35
MACD (12, 26)
Sell
Level -1.25
25-day Aroon Oscillator
Buy
Level 60
On Balance Volume
Neutral
Level 21.5M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (12.275)
Buy
CA Score (Annual)
Level (1.217)
Buy
Beneish M-Score (Annual)
Level (-2.6023)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-2.2019)
Buy
Piotroski F Score (Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (10)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Stock Forecast FAQ

In the current month, TECH has received 7 Buy ratings 5 Hold ratings, and 0 Sell ratings. The TECH average analyst price target in the past 3 months is $70.11.

  • Where Will Bio-Techne Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Bio-Techne share price will rise to $70.11 per share over the next 12 months.

  • What Do Analysts Say About Bio-Techne?

    Analysts are divided on their view about Bio-Techne share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bio-Techne is a Sell and believe this share price will drop from its current level to $51.00.

  • What Is Bio-Techne's Price Target?

    The price target for Bio-Techne over the next 1-year time period is forecast to be $70.11 according to 12 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.

  • Is TECH A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Bio-Techne is a Buy. 7 of 12 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of TECH?

    You can purchase shares of Bio-Techne via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bio-Techne shares.

  • What Is The Bio-Techne Share Price Today?

    Bio-Techne was last trading at $47.32 per share. This represents the most recent stock quote for Bio-Techne. Yesterday, Bio-Techne closed at $46.66 per share.

  • How To Buy Bio-Techne Stock Online?

    In order to purchase Bio-Techne stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

NVIDIA (NASDAQ:NVDA) and Broadcom (NASDAQ:AVGO) are two of the hottest…

Why Did Forge Global Stock Go Down?
Why Did Forge Global Stock Go Down?

Shares of Forge Global (NYSE:FRGE), a platform that allows accredited…

Is GlobalFoundries On The Verge Of A Breakout?
Is GlobalFoundries On The Verge Of A Breakout?

GLOBALFOUNDRIES Inc. (NASDAQ:GFS) is as a semiconductor foundry whose chips…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 38x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 45x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
58
WIX alert for May 22

Wix.com [WIX] is up 1.88% over the past day.

Buy
81
DY alert for May 22

Dycom Industries [DY] is down 0% over the past day.

Sell
50
FICO alert for May 22

Fair Isaac [FICO] is down 0.46% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock